Could skipping a common antibiotic be just as safe for heart infections?

NCT ID NCT07345325

Recruiting now Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This study compares two antibiotic approaches for a serious heart valve infection caused by staph bacteria. One group gets a standard treatment that includes the drug rifampin, while the other group gets a treatment without it. The goal is to see if skipping rifampin is just as effective at preventing death within six months. The trial plans to enroll 422 adults with infected prosthetic heart valves.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rifampin
What this could lead to: If successful, this could show that a simpler antibiotic regimen without rifampin is just as effective, reducing side effects and drug interactions for patients with this heart infection.
What could go wrong: This is a non-inferiority trial, so it may only prove the rifampin-free regimen is not worse, not better. The infection is serious, and treatment failure could be life-threatening.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial endocarditis endocarditis infective endocarditis staphylococcal infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFECTIVE ENDOCARDITIS

Contacts and locations

Locations

AP-HP hôpital St Antoine
RECRUITING

Paris, 75012, France
AP-HP, Groupe hospitalier Henri Mondor
RECRUITING

Créteil, 94010, France
AP-HP, Hôpital Pitié Salpétrière
RECRUITING

Paris, 75013, France
AP-HP, hôpital Bichat-Claude Bernard
NOT_YET_RECRUITING

Paris, 75018, France
CH Pau
RECRUITING

Pau, 64000, France
CH Tourcoing
RECRUITING

Tourcoing, 59200, France
CH intercommunal Cornouaille Quimper
RECRUITING

Quimper, 29000, France
CH metropole Savoie, Chambery, GHT Savoie-Belley, Site Aix les Bains
RECRUITING

Aix-les-Bains, 73100, France
CHD Vendée
RECRUITING

La Roche-sur-Yon, 85000, France
CHR Orléans
NOT_YET_RECRUITING

Orléans, 45067, France
CHU Angers
RECRUITING

Angers, 49933, France
CHU Besançon
NOT_YET_RECRUITING

Besançon, 25030, France
CHU Bordeaux, Cardiologic hospital of Haut lévêque
RECRUITING

Bordeaux, 33600, France
CHU Bordeaux, Haut Lévêque Hospital, Infectious disease department
RECRUITING

Bordeaux, 33600, France
CHU Brest
RECRUITING

Brest, 29200, France
CHU Dijon Bourgogne
RECRUITING

Dijon, 21000, France
CHU Grenoble
RECRUITING

Grenoble, 38043, France
CHU Lyon, La Croix-Rousse Hospital, Infective disease department
NOT_YET_RECRUITING

Lyon, 69317, France
CHU Lyon, Louis Pradel Hospital, Cardiology Institute
NOT_YET_RECRUITING

Lyon, 69677, France
CHU Montpellier
RECRUITING

Montpellier, 34090, France
CHU Nancy
RECRUITING

Nancy, 54035, France
CHU Nantes, Hôtel Dieu Hospital, Infective disease department
RECRUITING

Nantes, 44093, France
CHU Nantes, Laennec Hospital, Cardiology department
RECRUITING

Nantes, 44800, France
CHU Nice
RECRUITING

Nice, 06202, France
CHU Poitiers
RECRUITING

Poitiers, 86000, France
CHU Rennes
RECRUITING

Rennes, 35000, France
CHU St-Etienne
NOT_YET_RECRUITING

Saint-Etienne, 42270, France
CHU Strasbourg
RECRUITING

Strasbourg, 67000, France
CHU Toulouse, Purpan Hospital, Infectious disease department
RECRUITING

Toulouse, 31059, France
CHU Toulouse, Rangueil Hospital, Cardiology department
RECRUITING

Toulouse, 31400, France
CHU Tours
RECRUITING

Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.